Chang, Yun-Hsuan
Periñan, Maria Teresa
Wilson, Matt
Noyce, Alastair J. http://orcid.org/0000-0003-3027-5497
Funding for this research was provided by:
UMEDEOR LTD, 8 Warner Yard, London EC1R 5EY, UK
Article History
Received: 22 September 2023
Accepted: 2 February 2024
First Online: 19 March 2024
Competing interests
: Dr. Chang is an employee of UMEDEOR LTD and Cohort Science LTD, which sponsors the AccessPD registry. Dr. Wilson is the founder and Chief Executive Officer of UMEDEOR LTD and Cohort Science LTD, which sponsors the AccessPD registry. Dr. Periñan received consultancy fees from UMEDEOR LTD. Prof Noyce reports grants from Parkinson’s UK, Barts Charity, Cure Parkinson’s, National Institute for Health and Care Research, Innovate UK, Virginia Keiley benefaction, Solvemed, the Medical College of Saint Bartholomew’s Hospital Trust, Alchemab, Aligning Science Across Parkinson’s Global Parkinson’s Genetics Program (ASAP-GP2) and the Michael J Fox Foundation. Prof Noyce received consultancy fees during the design phase of AccessPD. Prof Noyce reports consultancy and personal fees from AstraZeneca, AbbVie, Profile, Roche, Biogen, UCB, Bial, Charco Neurotech, Alchemab, Sosei Heptares, and Britannia, outside the submitted work. Prof Noyce is an Associate Editor for the Journal of Parkinson’s Disease. The authors declare that there are no additional disclosures to report.